New hope for pancreatic cancer: targeted drug combo enters final trial phase

NCT ID NCT07079228

Recruiting now Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps people with advanced pancreatic cancer live longer. The study includes 602 adults whose tumors have a specific marker (CLDN18.2). Participants are randomly assigned to receive either QLS31905 or a placebo, both combined with chemotherapy. The main goal is to see if the drug improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLS31905 (an experimental drug) plus chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to: If it works, this could provide a new first-line treatment option for people with a specific type of advanced pancreatic cancer, potentially extending survival.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not improve survival or could cause side effects like infusion reactions or increased toxicity from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.